Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer

Journal of Gene Medicine

Volumn 6, Issue 12, 2004, Pages 1343-1357

  Martiniello Wilks, Rosetta ^a,d   Wang, Xiao Yang ^a   Voeks, Dale J ^a   Dane, Allison ^a   Shaw, Jan M ^c   Mortensen, Elin ^a,b   Both, Gerald W ^c   Russell, Pamela J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c CSIRO   (Australia)

^d CENTENARY INSTITUTE   (Australia)

Author keywords

Fludarabine phosphate; GDEPT; Ovine atadenovirus; PNP; Prostate; RM1 model

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; FLUDARABINE PHOSPHATE; PRODRUG; PURINE NUCLEOSIDE PHOSPHORYLASE; THY 1 ANTIGEN; VIRUS VECTOR;

ANALYSIS OF VARIANCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CELL INFILTRATION; CELL KILLING; CONTROLLED STUDY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; GENE THERAPY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LONG TERMINAL REPEAT; LUNG METASTASIS; LUNG PSEUDOTUMOR; MALE; METASTASIS INHIBITION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN SYNTHESIS; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR MODEL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CATTLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PRODRUGS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; PURINE-NUCLEOSIDE PHOSPHORYLASE; TRANSDUCTION, GENETIC; VIDARABINE PHOSPHATE;

EID: 14244249270     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.629     Document Type: Article

References (66)

1. Malkowicz SB, Johnson JO. Gene therapy for prostate cancer [Review]. Haematology-Oncology Clinics of North America 1998; 12 649-664.
2. Palapattu GS, Naitoh J, Belldegurn AS. Gene therapy for prostate cancer. New perspectives on an old problem. Urologic Clinics of North America 1999; 26: 353-363.
3. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: current status and future prospects. J Urol 2001; 166: 1220-1233.
4. Anderson WF. Gene therapy for cancer. Hum Gene Ther 1994; 5: 1-2.
5. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells to treatment of experimental brain tumours. Science 1992; 256: 1550-1552.
6. Freeman SM, Abboud CN, Wartenby KA, et al. The "bystander effect": tumour regression when a fraction of the tumour mass is genetically modified. Cancer Res 1993; 53: 5274-5283.
7. Moolten FL. Tumour chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-5281.
8. Elshami AA, Savredra A, Zhang H, et al. Gap junctions play a role in the bystander effect of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 1996; 3: 85-92.
9. Hermann JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Human Gene Ther 1999; 10: 1239-1249.
10. Shalev M, Miles BJ, Thompson TC, et al. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpes virus thymidine kinase gene. World J Urol 2000; 18: 125-129.
11. Hassan W, Sanford MA, Woo SL, Chen SH, Hall SJ. Prospects for herpes-simplex virus thymidine kinase and cytokine gene therapy as immunomodulatory gene therapy for prostate cancer. World J Urol 2000; 18: 130-135.
12. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and hormone-refractory prostate cancer. Human Gene Ther 2003; 14: 227-241.
13. Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Human Gene Ther 1996; 7: 515-523.
14. Timme TL, Hall SJ, Barrios R, Woo S, Aguilar-Cordova E, Thompson TC. Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice. Cancer Gene Ther 1998; 5: 74-82.
15. Martiniello-Wilks R, Garcia-Aragon J, Daja M, et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-prodrug systems delivered by identical adenovirus vectors. Human Gene Ther 1998; 9: 1617-1626.
16. Cheon J, Kim HK, Moon DG, Yoon DK, Cho JH, Koh SK. Adenovirus-mediated suicide gene therapy using the herpes virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. BJU Int 2000; 85: 759-766.
17. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
18. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumours together with a distant transduced tumour. Human Gene Ther 1997; 8: 1807-1814.
19. Hall SJ, Mutchnik SE, Chen SH, Woo SLC, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997; 70: 183-187.
20. Hall SJ, Sanford MA, Atkinson G, Chen SH. Induction of potent antitumour natural killer cell activity by herpes simplex virus thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res 1998; 58: 3221-3225.
21. Bi W, Kim YC, Feliciano ES, Pavelic ZP, Stambrook PJ. An HSVtk-mediated local and distant anti-tumour bystander effect in tumours of head and neck origin in athymic mice. Cancer Gene Ther 1997; 4: 246-252.
22. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of routine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
23. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted model. Cell 1989; 5: 917-930.
24. Voeks DJ, Martiniello-Wilks R, Russell PJ. Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urol Oncol 2002; 7: 111-118.
25. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
26. Sorscher EJ, Peng S, Bebok Z, Allan PW, Bennett LL Jr, Parker WB. Tumour cell bystander killing in colon carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines. Gene Ther 1994; 1: 233-238.
27. Parker WB, Allan PW, Shaddix SC, et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem Pharmacol 1998; 55: 1673-1681.
28. Lockett L, Molloy P, Russell P, Both G. Relative efficiency of tumour cell killing in vitro by two enzyme prodrug systems delivered by identical adenovirus vectors. Clin Cancer Res 1997; 3: 2075-2080.
29. Curlee KV, Parker WB, Sorscher EJ. Tumor sensitization to purine analogs by E coli PNP. Method in Molecular Medicine 2004; 90: 223-245.
30. Parker WB, Hong J, Allan PW, et al. Excellent in vivo bystander activity of fludarabine phosphate against D54 tumours that express the E coli purine nucleoside phosphorylase gene. Mol Ther 2003; 7(Supplement 1): 719.
31. Pulmann M, Gnant M, Brown CK, Alexander RH, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumour-directed gene therapy. Hum Gene Ther 1997; 10: 649-657.
32. Mohr L, Shankara S, Yoon S-K, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the E. coli purine nucleoside phosphorylase gene. Hepatology 2000; 31: 606-614.
33. Both G. Atadenoviruses. In The Springer Index of Viruses Tidona C, Darai G (eds). Springer-Verlag: Berlin, 2001; 11-17.
34. Wang XY, Martiniello-Wilks R, Shaw JM, et al. Preclinical evaluation of a prostate targeted gene directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 2004; in press.
35. Both G. Xenogenic adenoviruses. In Adenoviral Vectors for Gene Therapy, Curiel D, Douglas J (eds). Academic Press: San Diego, 2002; 447-479.
36. Greenberg NM, DeMayo FJ, Finegold M, Medina D, Tilley W, Aspinall J. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-3443.
37. Voeks DJ, Martiniello-Wilks R, Madden VM, et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 2002; 9: 759-768.
38. Martiniello-Wilks R, Voeks D, Dane A, et al. Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. J Gene Med 2004; 6: 43-54.
39. Cameron FH, Moghaddam M, Bender VJ, Whittaker RG, Mott MM, Lockett TJ. A transfection compound series based on a versatile Tris linkage. Biochim Biophys Acta 1999; 1417: 37-50.
40. Russell PJ, Raghavan D, Gregory P, et al. Bladder cancer xenografts: a model of tumour cell heterogeneity. Cancer Res 1986; 46: 2035-2040.
41. Martiniello-Wilks R, Dane A, Mortensen E, Jeyakumar G, Wang XY, Russell PJ. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Res 2003; 23: 2633-2642.
42. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
43. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics 2003. CA Cancer J Clin 2003; 53: 5-26.
44. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 4: 30-35.
45. Pisters LL. The challenge of locally advanced prostate cancer. Semin Oncol 1999; 26: 202-216.
46. LePage GA, Khaliq A, Gottlieb JA. Studies of 9-β-D-arabinofuranosyladenine in man. Drug Metab Dispos 1973; 1 756-759.
47. Carson DA, Kaye J, Wasson DB. Differences in deoxyadenosine metabolism in human and mouse lymphocytes. J Immunol 1980; 124 8-12.
48. Hutton JJ, Von Hoff DD, Kuhn J, Phillips J, Hersh M, Clarke G. Phase I clinical investigation of 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res 1984; 44: 4183-4186.
49. Kawakita M, Rao GS, Ritchey JK, et al. Effect of canarypox virus (ALVAC)-mediated cytokine expression on routine prostate tumour growth. J Natl Cancer Inst 1997; 89: 428-436.
50. Brockman RW, Cheng Y-C, Schabel FM Jr. Metabolism and chemotherapeutic activity of 9-β-D-arabinosyl-2-fluoroadenine against murine leukaemia L1210 and evidence of its phosphorylation by deoxycytidine kinase. Cancer Res 1980; 40: 3610-3615.
51. Hersh MR, Kuhn JG, Phillips JL, Clark G, Ludden TM, Von Hoff DD. Pharmacokinetic study of fludarabine phosphate (NSC312887). Cancer Chemother Pharmacol 1986; 17: 277-280.
52. Skipper HE, Montgomery JA, Thompson JR, Schabel FM Jr. Structure-activity relationships and cross-resistance observed on evaluation of a series of purine analogs against experimental neoplasms. Cancer Res 1959; 19: 425-437.
53. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ. In situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23: 31-45.
54. Ledbetter JA, Herzenberg LA. Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 1979; 47 63-90.
55. Trinite B, Voisine C, Yagita H, Josien R. A subset of cytolytic dendritic cells in rat. J Immunol 2000; 165: 4202-4208.
56. Radrizzani M, Carminatti H, Pivetta OH, Vargas VPI. Developmental regulation of Thy-1.2 rate of synthesis in the mouse cerebellum. J Neurosci 1995; 42: 220-227.
57. Henkart PA, Williams MS, Nakajima H. Degranulating cytotoxic T lymphocytes inflict multiple damage pathways on target cells. Curr Topics Microbiol Immunol 1995; 198: 75-86.
58. Burton RC. Natural killer cells and cancer: a review. Aust New Z J Surgery 1988; 58: 761-774.
59. Johnson R, Lancki DW, Fitch FW. Accessory molecules involved in antigen-mediated cytolysis and lymphokine production by cytotoxic T lymphocyte subsets. J Immunol 1993; 151: 2986-2992.
60. + natural T (NT) cells mediate immune surveillance against NK-sensitive and NK-resistant transplantable tumours in certain strains of inbred mice. Int J Cancer 1996; 66: 523-537.
61. + natural T (NT) cells. Int J Cancer 1997; 70: 450-460.
62. Alberola-IIa J, Takaki S, Kerner JD, Perlmutter RM. Differential signalling by lymphocyte antigen receptors. Ann Rev Immunol 1997; 15: 125-137.
63. Kojima H, Toda M, Sitkovski MV. Comparison of Fas- versus perforin-mediated pathways of cytotoxicity in TCR- and Thy-1-activated murine T cells. Int Immunol 2000; 12: 365-374.
64. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89
65. Henry F, Boisteau O, Bretaudeau L, Lieubeau B, Meflah K, Gregoire M. Antigen-presenting cells that phagocytose apoptotic tumour-derived cells are potent tumour vaccines. Cancer Res 1999; 59: 3329-3332.
66. Khrone TU, Shankara S, Geissler M, et al. Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma in vitro. Hepatology 2001; 34: 511-518.